Marianne Brodmann (Medical University of Graz, Graz, Austria) shared her opinions on some of the burning debates in peripheral arterial disease (PAD) treatment at the Paris Vascular Insights course (PVI; 12–14 December, Paris, France).
On the ongoing competition between sirolimus and paclitaxel, Brodmann remarked that, while paclitaxel is “still the winner above the knee,” limus remains under evaluation. As a result, she stressed that the final conclusion of the debate is “on hold for now”.
Brodmann also weighed in on the discussion surrounding bioresorbable versus non-resorbable scaffolds. After underlining her support for a ‘leave nothing behind’ approach to avoid reinterventions with regard to restenosis, Brodmann shared that she is “very positive” there will be good data for bioresorbable devices in the near future.
Brodmann also considers the treatment of patients with extensive vascular calcification, which she noted is becoming an increasingly prevalent problem.
Brodmann commented that there are several new technologies in the works in this space, with Shockwave’s intravascular lithotripsy offering represents the “first-line” treatment.
